Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3252W HIGH $2.69
Volume
261.89 K
Value Traded
477.78 K
Short % Float
19.48%
-3.81%Week
-18.62%1 Month
-6.2%3 Month
-37.95%6 Month
-99.09%5 Year
-99.08%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
18.97 M
EPS (TTM)
-0.95
P/E Ratio
-
Ent. Value
11.66 M
Total Shares
33.27 M
Float Shares
29.82 M
Insiders
10.38%
Institutions
27.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
JSPR Catalyst Timeline
Dated clinical, regulatory and corporate events for Jasper Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jasper Therapeutics, Inc.
296Total events
10Upcoming
57Tier-1 (high impact)
2021 to 2030Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Jasper commences cash offer to purchase outstanding warrants at $0.324 per warrant
●Grant / FundingCorporate
Inducement stock option grants to three new employees (243,000 shares)
▲Partnership / LicenseKP-301Corporate
Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics
▲Partnership / LicenseKP-402Corporate
Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics
◆Pipeline PrioritizationCorporate
Board initiates comprehensive review of strategic alternatives to maximize shareholder value
◆Trial InitiationBriquilimabFiledTrial
Phase 2b CSU study planned to commence mid-2026
chronic spontaneous urticariasource ↗
●FDA Filing AcceptedBriquilimabFiledRegulatory Filing
Refiled updated Phase 2b protocol with FDA
chronic spontaneous urticaria (CSU)source ↗
◆Trial InitiationBriquilimabFiledTrial
Phase 2b CSU study commencement expected in mid-2026
chronic spontaneous urticariasource ↗
▲Full ResultsBriquilimabFiledClinical Data
Positive preliminary data from ETESIAN study: reductions in airway hyperresponsiveness and suppressed eosinophilic response
asthmasource ↗
◆Oral PresentationPresentation
Jasper Therapeutics to present at 46th Annual TD Cowen Healthcare Conference
▲Full ResultsBriquilimabFiledClinical Data
Updated data from open label extension: 75% complete response or well controlled disease at 12 weeks
chronic spontaneous urticariasource ↗
◆Oral PresentationBriquilimabFiledPresentation
Investor webinar to present updated data from open-label extension study in CIndU
CIndUsource ↗
▲Topline ReadoutBriquilimabFiledClinical Data
75% of CSU participants in open label extension achieved complete response or well controlled disease at 12 weeks
chronic spontaneous urticaria (CSU)source ↗
◆Timing GuidanceBriquilimabFiledPresentation
Last wave of BEACON data expected in Q1 2026
chronic spontaneous urticariasource ↗
▲Full ResultsBriquilimabFiledClinical Data
75% of CSU participants in OLE achieved complete response or well controlled disease at 12 weeks
chronic spontaneous urticariasource ↗
◆Oral PresentationBriquilimabFiledPresentation
Findings from investigation into anomalous BEACON study results presented at investor webinar
chronic spontaneous urticariasource ↗
▲Topline ReadoutBriquilimabFiledClinical Data
Positive preliminary data from ETESIAN study of briquilimab in asthma
asthmasource ↗
◆Enrollment UpdateBriquilimabFiledTrial
Investigation into 240mg Q8W and 240mg/180mg Q8W cohorts ongoing; plan to add 10-12 new patients and redose
chronic spontaneous urticaria (CSU)source ↗
◆Topline ReadoutBriquilimabFiledClinical Data
Data from new patients and redosed patients in BEACON 240mg cohorts
chronic spontaneous urticaria (CSU)source ↗
◆Timing GuidanceBriquilimabFiledPresentation
Plan to complete investigation of anomalous efficacy results in BEACON study and report final conclusions
chronic spontaneous urticaria (CSU)source ↗
◆Topline ReadoutBriquilimabFiledClinical Data
Plan to report initial data from ETESIAN study in allergic asthma
allergic asthmasource ↗
◆Trial InitiationBriquilimabFiledTrial
Planned Phase 2b study expected to commence in Q4 2025
chronic spontaneous urticariasource ↗
◆Enrollment UpdateBriquilimabFiledTrial
Plan to enroll additional 10-12 patients in 240mg Q8W and 240mg/180mg Q8W cohorts
chronic spontaneous urticariasource ↗
▼Equity OfferingCorporate
Pricing of $30 million public offering of common stock, pre-funded warrants and common warrants
▼Equity OfferingCorporate
Proposed public offering of common stock, pre-funded warrants and common warrants
◆Oral PresentationBriquilimabFiledPresentation
H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat
◆Oral PresentationBriquilimabFiledPresentation
Cantor Fitzgerald Global Healthcare Conference 2025 Fireside Chat
▲Topline ReadoutBriquilimabFiledClinical Data
BEACON study: 89% complete response in 240mg and 360mg single-dose cohorts
chronic spontaneous urticaria (CSU)source ↗
◆Management ChangeCorporate
Dr. Edwin Tucker departing as CMO; Dr. Daniel Adelman appointed Acting CMO
▼Program DiscontinuationCorporate
Halting other clinical and preclinical programs to focus on chronic urticaria
▲Full ResultsBriquilimabFiledClinical Data
Updated data from BEACON study: 89% complete response in 240mg and 360mg single-dose cohorts
chronic spontaneous urticariasource ↗
Past FDA Catalysts and PDUFA Decisions
How JSPR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | briquilimab | Phase 1b/2a data readout | Phase 1b/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 90%
Micro Cap(rank 594 of 660)
Percentile Rank
Jasper Therapeutics, Inc. faces pipeline headwinds (22/100), with $214M risk-adjusted pipeline value, led by Humanized anti-CD117 Monoclonal Antibody in MYELODYSPLASTIC SYNDROME; MDS (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Humanized anti-CD117 Monoclonal Antibody Monoclonal antibodyCompletedNCT04429191 | MYELODYSPLASTIC SYNDROME; MDS | Phase 1 | COMPLETED | 32 | Jun 13, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every JSPR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| briquilimab OrphanRare Pediatric | chronic spontaneous urticaria, chronic inducible urticaria, asthma | 2026-02-25 | positive clinical outcomes in CSU, CIndU and allergic asthmaRead More | Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Crutcher Patrick JDirector | Buy | 888 888 held | $0.00 | 07/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JSPR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 10.00 K | 24.09 K |
JSPR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JSPR ranks across every disease it competes in
Competitive Position is a premium feature
See how JSPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJSPR News
JSPR▲ +1.8%today
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Jasper Therapeutics has initiated an offer to purchase all outstanding warrants issued in its public offering on September 18, 2025. The offer price is set at $0.324 per warrant, aiming to reduce potential dilution from warrant exercises. The offer will remain open until November 6, 2026, unless extended or terminated earlier.
Read more →JSPRJasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper Therapeutics has appointed Lisa Pitt as Senior VP of Regulatory Affairs and Shiguang Liu as VP of Clinical Development. These appointments follow the company's merger with Kira Pharmaceuticals and aim to bolster the development of their therapies for immune-mediated diseases. Both leaders bring extensive experience in their respective fields, enhancing Jasper's capabilities in regulatory and clinical development.
Read more →JSPRJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Jasper Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The presentation will take place on September 16 at 8:00 AM ET in a fireside chat format. The company focuses on developing therapies for immune-mediated diseases and has a promising pipeline.
Read more →JSPR▼ -5.5%on this news
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics has successfully closed its acquisition of Kira Pharmaceuticals, enhancing its portfolio with clinical stage assets targeting immunologically-driven disorders. The company also completed a PIPE financing, securing $132 million in gross proceeds. This strategic move positions Jasper Therapeutics for future growth and development in the biopharma sector.
Read more →JSPR▲ +14.3%on this news
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Jasper Therapeutics has completed its acquisition of Kira Pharmaceuticals in an all-stock transaction, enhancing its portfolio of biologic agents aimed at treating immunologically-driven disorders. The merger is supported by a $132 million private investment, expected to fund operations through 2028. The combined company will focus on advancing multiple innovative therapies, including KP-104 and briquilimab, with key clinical milestones anticipated in the coming years.
Read more →JSPR▼ -35.6%on this news
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Jasper Therapeutics is undergoing a strategic review to explore alternatives for maximizing shareholder value. This includes potential asset sales, collaborations, or a merger. The company will also implement cost-saving measures while ensuring compliance with regulatory requirements. However, there is no set timeline for this process, and outcomes remain uncertain.
Read more →JSPRJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q1 2026, highlighting advancements in the briquilimab development program for chronic spontaneous urticaria (CSU). The company refiled its Phase 2b protocol with the FDA and reported positive clinical outcomes, with a significant percentage of patients achieving a complete response. Despite a net loss of $1.2 million, Jasper aims to commence the Phase 2b study in the second half of the year.
Read more →JSPR▼ -14.3%on this news· ran to -34% by day 3
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q4 and year-end 2025, highlighting the promising data for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company is preparing to initiate a Phase 2b/3 study in CSU, with patient enrollment expected in the second half of 2026. Additionally, preliminary data from the ETESIAN study in asthma showed positive outcomes, although future developments will depend on strategic partnerships and available capital.
Read more →JSPRJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Jasper Therapeutics will present at the 46th Annual TD Cowen Healthcare Conference from March 2-4, 2026. The company focuses on briquilimab, an antibody therapy for mast cell driven diseases like chronic spontaneous urticaria and asthma. The presentation will include a fireside chat on March 2, 2026, at 3:50 PM EST.
Read more →JSPR▼ -19%on this news
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
Jasper Therapeutics reported positive updated data from clinical studies of briquilimab for chronic spontaneous urticaria (CSU). In the BEACON study, 67% of enrolled patients achieved a complete response after 12 weeks. Similarly, the open-label extension study showed that 75% of CSU participants achieved control of their disease. The favorable safety profile and low incidence of adverse events support further development of briquilimab.
Read more →JSPR▲ +7.9%on this news· ran to -22% by day 3shared move
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Jasper Therapeutics has appointed Jeet Mahal as its new CEO, succeeding Ronald Martell, who led the company through significant transitions since his appointment in 2022. Mahal brings over thirty years of experience in the life sciences industry, including pivotal roles at Jasper. The company is set to commence its registrational program for its lead therapeutic, briquilimab, aimed at treating mast cell-driven diseases, including chronic spontaneous urticaria (CSU). An investor webinar is scheduled for January 8, 2026, to present updated data from the BEACON study related to CSU.
Read more →JSPR▼ -8.1%on this news
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Jasper Therapeutics reported positive preliminary data from the ETESIAN Phase 1b study of briquilimab, showing significant reductions in airway hyperresponsiveness and eosinophils in asthma patients. The drug demonstrated a favorable safety profile. Additionally, Jasper concluded its internal investigation into the BEACON study, attributing unexpected results to patient selection issues rather than drug efficacy.
Read more →JSPR▼ -8.1%on this news
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Jasper Therapeutics will host an investor webinar on December 2nd to present preliminary findings from the ETESIAN study in asthma and discuss the BEACON study results. The event will feature remarks from company management and Dr. Martin Metz, a leading investigator. A Q&A session will follow the presentation.
Read more →JSPRJasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q3 2025 and provided updates on briquilimab, an antibody therapy targeting mast cell diseases. The company is investigating efficacy results from the BEACON study and plans to report data from ongoing studies in the coming months. The CEO expressed optimism about briquilimab's potential in treating chronic urticaria and asthma.
Read more →JSPR▼ -13.8%on this newsshared move
Jasper Therapeutics to Present at Upcoming Investor Conferences
Jasper Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference. The company is focused on briquilimab, a monoclonal antibody targeting mast cell diseases. Briquilimab has shown positive clinical outcomes in treating chronic spontaneous urticaria and chronic inducible urticaria.
Read more →JSPRJasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Jasper Therapeutics has announced the pricing of a public offering, aiming to raise approximately $30 million. The offering consists of common stock and warrants, which will be used to advance the development of briquilimab, a therapy for mast cell-driven diseases. The offering is expected to close on September 22, 2025, subject to customary conditions.
Read more →JSPRJasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Jasper Therapeutics announced a proposed public offering of common stock and warrants to fund the development of briquilimab, a treatment for mast cell-driven diseases. The offering is subject to market conditions, and the company intends to use the proceeds for clinical advancements and general corporate purposes. TD Cowen will manage the offering, which is registered with the SEC.
Read more →JSPRJasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics reported its financial results for Q2 2025, highlighting positive developments for its investigational therapy briquilimab. Significant response rates were noted across various patient cohorts, particularly in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). However, the company is currently investigating some cohorts that did not meet anticipated performance metrics. Future clinical outcomes and financial health depend on ongoing trials and market conditions, presenting both potential and risk.
Read more →JSPR▲ +21.9%on this news
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jasper Therapeutics has announced a corporate reorganization aimed at extending its cash runway, which includes a significant workforce reduction of about 50%. The company will focus its resources on the development of briquilimab for chronic urticaria, ceasing other clinical programs. Dr. Daniel Adelman has been appointed as the Acting Chief Medical Officer following the departure of Dr. Edwin Tucker.
Read more →About Jasper Therapeutics, Inc.
Headquarters2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA, 94065
BIOPHARMAWATCH ELITE PLUS
Trade the next JSPR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime